What is William Blair’s Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at William Blair issued their Q1 2025 EPS estimates for Neurogene in a research report issued to clients and investors on Tuesday, March 25th. William Blair analyst S. Corwin anticipates that the company will earn ($0.92) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS and FY2026 earnings at ($4.60) EPS.

Separately, HC Wainwright decreased their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $59.80.

Neurogene Price Performance

Shares of NGNE stock opened at $14.52 on Thursday. The business’s fifty day moving average price is $16.88 and its 200 day moving average price is $28.82. The firm has a market capitalization of $215.69 million, a PE ratio of -3.40 and a beta of 1.01. Neurogene has a 1-year low of $13.47 and a 1-year high of $74.49.

Neurogene (NASDAQ:NGNE) last issued its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the sale, the chief financial officer now directly owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.92% of the stock is currently owned by insiders.

Institutional Trading of Neurogene

Institutional investors and hedge funds have recently modified their holdings of the business. Casdin Capital LLC increased its stake in shares of Neurogene by 146.9% during the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock worth $29,612,000 after purchasing an additional 770,745 shares in the last quarter. FMR LLC grew its holdings in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after buying an additional 659,515 shares during the last quarter. JPMorgan Chase & Co. increased its position in Neurogene by 10,395.3% during the fourth quarter. JPMorgan Chase & Co. now owns 481,001 shares of the company’s stock worth $10,996,000 after buying an additional 476,418 shares in the last quarter. Samsara BioCapital LLC raised its holdings in shares of Neurogene by 35.4% in the fourth quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock worth $39,254,000 after acquiring an additional 449,337 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Neurogene in the fourth quarter worth $10,245,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.